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VENTURE-AF: A RANDOMIZED GLOBAL TRIAL EVALUATING UNINTERRUPTED RIVAROXABAN AND VITAMIN K ANTAGONISTS IN PATIENTS UNDERGOING CATHETER ABLATION FOR NONVALVULAR ATRIAL FIBRILLATION
Introduction: The uninterrupted vitamin K antagonist (VKA) strategy for catheter ablation (CA) of atrial fibrillation (AF) has been shown to be safe and continues to gain acceptance globally as a preferred approach. Although several observational studies suggest the practicality of using a novel oral anticoagulant (NOAC) periprocedurally, there is a general consensus that the need exists for a more rigorous evaluation of the use of uninterrupted NOACs in this setting. This is the first randomized study to evaluate the safety and efficacy of uninterrupted rivaroxaban and uninterrupted VKA therapy in patients with nonvalvular (NV) AF undergoing CA. Methods: This was a global-multicenter, phase 3b, randomized (1:1), open-label, active-controlled study in AF patients undergoing CA with uninterrupted rivaroxaban or uninterrupted VKA. Up to 5 weeks prior to CA, patients with NVAF were assigned to either uninterrupted rivaroxaban 20 mg once-daily or to uninterrupted VKA and study drugs were continued for 30 days after CA. The primary endpoint was major bleeding events up to 30 days after CA. Secondary endpoints included the occurrence of thromboembolic events (myocardial infarction, stroke, systemic embolization, or vascular death), other bleeding events and other adverse events (AEs). Endpoints were adjudicated by an independent blinded CEC using GUSTO, ISTH, and TIMI bleeding criteria. Application: A total of 248 patients were randomized at 46 sites in 5 countries. A total of 221 patients underwent CA. No patients were lost to follow-up. The average age was 59.5 ± 10 (SD) years, the estimated mean CHA2DS2-VASc was 1.6 and the diagnosis of paroxysmal AF was present at baseline in 73.4% of the patient population. For the period during and following CA, there was 1 ISTH major bleeding event in the VKA treatment group and no GUSTO severe/life threatening or TIMI major bleeding events. There was 1 ischemic stroke and 1 vascular death event in the VKA treatment group. 
LBCT01-05 WIRELESS LV ENDOCARDIAL STIMULATION FOR CRT: PRIMARY RESULTS OF THE SAFETY AND PERFORMANCE OF ELECTRODES IMPLANTED IN THE LEFT VENTRICLE (SELECT-LV) STUDY
Vivek Y. Reddy, MD, Petr Neuzil, MD, Sam Riahi, MD, Peter Søgaard, MD, Christian Butter, MD, Thomas Schau, MD, Peter Paul Delnoy, MD, Lieselot van Erven, MD, Martin Schalij, MD and Lucas Boersma, MD. Mount Sinai School of Medicine, New York, NY, Homolce Hospital, Prague, Czech Republic, Aalborg University Hospital, Aalborg, Denmark, Heart Centre, Bernau bei Berlin, Bernau, Germany, Isala Hospital, Zwolle, Netherlands, Leiden University Medical Centre, Leiden, Netherlands, St. Antonius Hospital, Nieuwegein, Netherlands Introduction: Indicated patients do not benefit from conventional CRT (ConCRT) because of lead issues such as an inability to place the CS lead or lack of clinical improvement with CRT. LV endocardial pacing has been proposed as a potential solution. We assessed the safety and performance of the novel Wireless Cardiac Stimulation System, WiCS-LV, to provide endocardial LV stimulation. Methods: SELECT-LV is a non-randomized, 6 EU-center study of CRT-indicated pts with either a failure of ConCRT, or requiring an upgrade but unsuitable for ConCRT. The WiCS-LV includes a 9mm leadless pacing electrode implanted at the endocardial mid-lateral LV free wall, using a retrograde aortic approach with a steerable 12Fr sheath; fluoroscopy and TTE/ICE helped assess LV wall thickness at potential implant locations. The electrode is activated by a submuscular ultrasonic transmitter (Tx) synchronized to RV pacing pulse of a standard ICD / pacemaker. The Tx is connected to a battery implanted subcutaneously in the left mid-axillary line. The primary efficacy endpoint was successful CRT by 12 lead EKG at 1 mo post-implant. Primary safety events included device / procedure complications within 24 h and at 1 mo. Application: Of 39 enrolled pts, 3 did not have an adequate acoustic window and 1 withdrew pre-implant. Implant was attempted in 35 (90%): age 65±8 yrs, 30 male, 15 ischemic CM (43%), EF 25.6±6.4%, NYHA 2.7±0.5 and baseline QRS 174±29 ms. Implantation was successful in 34 (97%); one pt had intra-operative VF precluding continuation. The most common indication for WiCS was the inability to perform CS pacing (24, 69%). Of the 27 pts followed for 1 mo, 96% achieved the primary endpoint, consistent CRT. At 1 month, the mean QRS reductions were 36.8ms and 52.7ms as compared with intrinsic and RV pacing, respectively; this was maintained in pts at 6 mo (n=19). Complications were separated into procedure-related (5, 15%), procedure and device related (1, 3%), unrelated (1, 3%), and as yet unadjudicated (3 including 1 death 4 days after aborted implant, 9%). Next steps / Future: This multicenter experience has demonstrated the feasibility of direct, wireless endocardial LV pacing to achieve CRT.
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THE EVERA MRI STUDY Introduction: Magnetic resonance imaging (MRI) of conventional implantable cardioverter-defibrillators (ICD) is contraindicated due to potential patient (pt) risks of MRI. We evaluated the safety and efficacy of an ICD system specially designed for full body MRI without restrictions on heart rate or pacing dependency. Methods: The Evera MRI Study was a multicenter, randomized evaluation of pts with de novo eligibility for an ICD. Pts received an Evera MRI single or dual chamber ICD connected to pre-specified leads. Pts were assigned 2:1 to undergo MR imaging at 1.5 T of the cardiac, thoracic, cervical and head regions to maximize radiofrequency exposure up to 2W/kg specific absorption rate (SAR) and gradient field exposure to 200 T/m/s (MRI group, n=175) or a 1-hour waiting period without MRI (control, n=88). The composite primary safety objective was >90% freedom from MRI-related complication within 30 days post-MRI and sustained tachyarrhythmia occurring during MRI. The co-primary efficacy endpoints compared changes from the pre-MRI/waiting period to 1 month later between groups for ventricular pacing capture threshold (VPCT) (non-inferiority test, 10% margin) and ventricular sensed amplitude (8% margin). A subset of MRI group pts underwent ventricular fibrillation (VF) induction testing post-MRI to characterize arrhythmia sensing, detection and therapy.
Results: In 42 centers, 275 pts were enrolled (76% male, age 60.4±13.8 yrs, 74% primary prevention indication). The safety endpoint was met with 100% freedom from the composite endpoint (p<0.0001). Both efficacy endpoints were also met with minimal differences in the proportion of MRI and control pts who demonstrated a ≤0.5 V increase in VPCT (100% MRI vs 98.2% control, non-inferiority p<0.0001, Figure) or a ≤50% decrease in R-wave amplitude (99.3% MRI vs 98.8% control, non-inferiority p=0.0001). Thirty-four VT/VF episodes (20 induced; 14 spontaneous) occurred in 24 subjects post-MRI, with no impact to sensing, detection or treatment observed. Conclusion: This is the first in human randomized study of an ICD system designed for full body MRI at 1.5 T. This system is safe and the MRI scan does not adversely affect the electrical performance or treatment of ventricular arrhythmias of the ICD system.
